Di-(2-aethoxycarbonylaethyl)-t-butylamin | 1462-99-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Di-(2-aethoxycarbonylaethyl)-t-butylamin
• 英文别名: 3-[tert-butyl-(2-ethoxycarbonyl-ethyl)-amino]-propionic acid ethyl ester；3,3'-tert-butylimino-di-propionic acid diethyl ester；Bis-(2-aethoxycarbonyl-aethyl)-tert-butyl-amin；3,3'-tert-Butylimino-di-propionsaeure-diaethylester；ethyl 3-[tert-butyl-(3-ethoxy-3-oxopropyl)amino]propanoate
• CAS: 1462-99-3
• 化学式: C₁₄H₂₇NO₄
• 分子量: 273.373
• InChiKey: PQVPLEDVLIMIMC-UHFFFAOYSA-N

物化性质

• 沸点：
  143-146 °C(Press: 2.5 Torr)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Di-(2-aethoxycarbonylaethyl)-t-butylamin 在 乙醇 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 24.0h， 以8.4 g的产率得到Ethyl 1-tert-butyl-4-oxopiperidine-3-carboxylate
  参考文献：
  名称：

  5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity

  摘要：

  Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and cancer. Several pieces of evidence across different species, including primates, underscore the implication of the histamine 3 receptor (H3R) in the regulation of food intake and body weight and the potential therapeutic effect Of H3R inverse agonists. A pharmacophore model, based on public information and validated by previous investigations, was used to design several potential scaffolds. Out of these scaffolds. the 5-hydroxyindole-2-carboxylic acid amide appeared to be of great potential as a novel series of H-3 inverse agonist. Extensive structure-activity relationships revealed the interconnectivity of microsomal clearance and hERG (human ether-a-go-go-related gene) affinity with lipophilicity, artificial membrane permeation, and basicity. This effort led to the identification of compounds reversing the (R)-alpha-methylhistamine-induced water intake increase in Wistar rats and, further, reducing food intake in diet-induced obese Sprague-Dawley rats. Of these, the biochemical, pharmacokinetic, and pharmacodynamic characteristics of (4,4-difluoropiperidin-1-yl)[1-isopropyl-5-(1-isopropylpiperidin-4-yloxy)1H-indol-2-yl]-methanone 36 are detailed.

  DOI：

  10.1021/jm900409x
• 作为产物：
  描述：

  丙烯酸乙酯 、 3-(叔丁基氨基)丙酸乙酯 以27%的产率得到
  参考文献：
  名称：

  BARBULESCU, N.;BORNAZ, C.;BARBULESCU, E.;MOGA-GHEORGHE, S.;ZAVOIANU, D., REV. CHIM., RSR, 1983, 34, N 7, 583-587

  摘要：

  DOI：

文献信息

• 5-Aminoindole derivatives as H3 inverse agonists
  申请人：Nettekoven Heinrich Matthias

  公开号：US20060160855A1

  公开（公告）日：2006-07-20

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中R1、R2、R3、R4和m定义如描述和权利要求所述，以及药用可接受的盐以及包含这些化合物的药物组合物以及它们的制备方法。这些化合物用于治疗和/或预防与调节H3受体相关的疾病。
• 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS
  申请人：Nettekoven Matthias Heinrich

  公开号：US20090069311A1

  公开（公告）日：2009-03-12

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和m如描述和权利要求中所定义，以及其药学上可接受的盐，以及包含这些化合物的制药组合物和其制备方法。这些化合物对于治疗和/或预防与H3受体调节相关的疾病是有用的。
• 5-aminoindole derivatives as H3 inverse agonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07754736B2

  公开（公告）日：2010-07-13

  The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和m如描述和权利要求中所定义，并且其药学上可接受的盐，以及包含这些化合物的制药组合物和其制备方法。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• t-Carbinamines, RR'R”CNH₂. II. Cyanoalkylations and Related Reactions¹
  作者：Leo S. Luskin、M. J. Culver、G. E. Gantert、W. E. Craig、R. S. Cook

  DOI：10.1021/ja01597a049

  日期：1956.8
• BARBULESCU, N.;BORNAZ, C.;BARBULESCU, E.;CUZA, O.;MOGA-CHEORGHE, S.;ZAVOI+, REV. CHIM., RSR, 1983, 34, N 8, 699-701
  作者：BARBULESCU, N.、BORNAZ, C.、BARBULESCU, E.、CUZA, O.、MOGA-CHEORGHE, S.、ZAVOI+

  DOI：——

  日期：——